About TRUEinvivo
TRUEinvivo is a Healthcare company based in Guildford (United Kingdom) founded in 2014 by Shakar Jafari. Micro silica bead array detectors for radiotherapy doses are developed. TRUEinvivo has raised $1.24 million across 7 funding rounds. The company has 8 employees. Its chief executive, as recorded, is Nigel Biggs. TRUEinvivo offers products and services including DOSEmapper1D™, DOSEmapper2D™, and DOSEmapper3D™. Its focus areas include Life Sciences, Imaging Diagnostics, Accessories and Dosimetry System. Its legal entity is TRUEINVIVO LIMITED.
Company details
TRUEinvivo was founded in 2014 in Guildford, United Kingdom, as a developer of medical devices in the radiotherapy sector. Micro silica bead array thermoluminescent detectors, known as DOSEmapper, are produced to measure radiation doses delivered to tumors during treatment. Operations focus on precision dosimetry tools for clinical applications, with the companys domain registered as trueinvivo.co.uk. Key personnel include founder Shakar Jafari and CEO Nigel Biggs.
- Headquarters Guildford, United Kingdom
- Employees 8
- Founders Shakar Jafari
- SectorsHealthcare
- Email••••••••
- Website trueinvivo.co.uk
- Social LinkedIn X Facebook
- Legal Name Trueinvivo Limited
- Date of Incorporation 02 Dec, 2014
- Jurisdiction GODALMING, SURREY
- Total Equity Funding$1.24M (USD)
in 7 rounds
- Latest Funding Round$152.74K (USD), Seed
Oct 2023
- Employee Count8
Products & Services of TRUEinvivo
TRUEinvivo offers a comprehensive portfolio of products and services, including DOSEmapper1D™, DOSEmapper2D™, and DOSEmapper3D™.
Measures tumor radiation dose with high resolution via catheter.
Flexible matrix for accurate radiation measurement in curved areas.
Spiral-wrapped system for mapping doses in organs at risk.
Funding Insights of TRUEinvivo
TRUEinvivo has successfully raised a total of $1.24M across 7 strategic funding rounds. The most recent funding activity was a Seed round of $152.74 thousand completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.24M
- Total Rounds 7
- Last Round Seed — $152,735
- First Round $159,908
(Feb 2018)
All 7 funding rounds of TRUEinvivo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $152,735 | Seed | – | – | – |
| Jan 2023 | $205,984 | Seed | – | – | – |
| Jan 2021 | $150,997 | Seed | – | – | – |
| Jun 2019 | $233,726 | Seed | – | – | – |
| Jan 2019 | $213,127 | Seed | – | – | – |
| Apr 2018 | $119,762 | Seed | – | – | – |
| Feb 2018 | $159,908 | Seed | – | – | – |
People of TRUEinvivo
3 people are tracked at TRUEinvivo (3 in leadership); the tracked headcount is 8.
| Name | Role | Group |
|---|---|---|
Shakar Jafari | Founder | Leadership |
Nigel Biggs | CEO | Leadership |
Mike Stroud | Engineering Director | Leadership |
Complete people profiles for TRUEinvivo
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of TRUEinvivo
3 dated milestones of TRUEinvivo across 9 years, from founding to its latest funding, stage changes and deals.
- Founded TRUEinvivo is founded.
- Funding First funding round of $160K.
- Funding Latest funding round, Seed, of $153K.
Top companies in Imaging Diagnostics
2 companies that operate in the same segment as TRUEinvivo (Imaging Diagnostics) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Technology tools and systems for molecular scale are developed. | 1959 | Abingdon, Oxfordshire, United Kingdom | USD 648.1 M | |||
Planar X-ray radiology products for diagnostic imaging are supplied. | 2000 | Oxford, Oxfordshire, United Kingdom | USD 43.43 M | USD 1.04 M | 50 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about TRUEinvivo
TRUEinvivo was founded in 2014 and raised its 1st funding round 4 years after it was founded.
TRUEinvivo is headquartered in Guildford, United Kingdom.
Nigel Biggs is the CEO of TRUEinvivo, as recorded in our data.
TRUEinvivo is a funded company, having raised a total of $1.24M across 7 funding rounds to date. The company's 1st funding round was a Seed of $159.91K, raised on Feb 2018.
TRUEinvivo has 8 employees.
TRUEinvivo was founded in 2014 in Guildford, United Kingdom, as a developer of medical devices in the radiotherapy sector. Micro silica bead array thermoluminescent detectors, known as DOSEmapper, are produced to measure radiation doses delivered to tumors during treatment. Operations focus on precision dosimetry tools for clinical applications, with the companys domain registered as trueinvivo.co.uk. Key personnel include founder Shakar Jafari and CEO Nigel Biggs.
TRUEinvivo offers DOSEmapper1D™, DOSEmapper2D™, and DOSEmapper3D™.
TRUEinvivo operates through Trueinvivo Limited.